Table 3.
Multivariate analysis of transplant outcomes in intermediate-risk AML adults with FLT3-ITD transplanted in CR1 MRD negative.
| RI | NRM | LFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| HAPLO vs ASCT | 0.14 (0.07–0.28) | <0.0001 | 3.43 (1.55–7.61) | 0.002 | 0.53 (0.34–0.85) | 0.007 | 0.83 (0.52–1.33) | 0.44 |
| Age (per 10 years) | 0.86 (0.71–1.05) | 0.14 | 1.54 (1.17–2.02) | 0.002 | 1.09 (0.94–1.27) | 0.27 | 1.19 (1–1.4) | 0.048 |
| Year of HSCT | 0.95 (0.88–1.03) | 0.25 | 0.87 (0.78–0.97) | 0.013 | 0.93 (0.87–1) | 0.04 | 0.9 (0.84–0.97) | 0.004 |
| Female vs male | 1.21 (0.73–2) | 0.45 | 1.54 (0.86–2.78) | 0.15 | 1.34 (0.92–1.96) | 0.13 | 1.55 (1.02–2.37) | 0.042 |
| Time diagnosis to HSCT (mo) | 0.98 (0.88–1.1) | 0.76 | 0.94 (0.81–1.08) | 0.36 | 0.96 (0.88–1.05) | 0.38 | 0.96 (0.88–1.05) | 0.37 |
| NPM1 mut vs wt | 0.46 (0.26–0.8) | 0.006 | 0.6 (0.33–1.1) | 0.1 | 0.5 (0.33–0.76) | 0.001 | 0.56 (0.36–0.87) | 0.009 |
| China vs other countries | 1.18 (0.32–4.36) | 0.81 | 0.7 (0.23–2.15) | 0.54 | 0.78 (0.31–1.97) | 0.6 | 0.63 (0.27–1.47) | 0.29 |
HR hazard ratio, CI confidential interval, HAPLO haploidentical stem cell transplantation, ASCT autologous stem cell transplantation, HSCT hematopoietic stem cell transplantation, mo months, mut mutation, wt wild-type.